Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.

A, Damask; PG, Steg; GG, Schwartz; M, Szarek; E, Hagström; L, Badimon; MJ, Chapman; C, Boileau; S, Tsimikas; HN, Ginsberg; P, Banerjee; G, Manvelian; R, Pordy; S, Hess; JD, Overton; LA, Lotta; GD, Yancopoulos; GR, Abecasis; A, Baras; C, Paulding

doi:10.1161/circulationaha.119.044434

Public

Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.

Shared by NobleBlocks on Nov 11, 2019 • 12:00 AM UTC

Authors:

Damask A

Steg PG

Schwartz GG

Abstract

<h4>Background</h4>Alirocumab, an antibody that blocks PCSK9 (proprotein convertase subtilisin/kexin type 9), was associated with reduced major adverse cardiovascular events (MACE) and death in the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During ...

Subject

Genetics

Pharmacogenomics

Genomics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!